Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin (2017 - 2026)

Akebia Therapeutics has reported EBT Margin over the past 9 years, most recently at 19.5% for Q4 2025.

  • Quarterly EBT Margin rose 2955.0% to 19.5% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.58% through Dec 2025, up 4176.0% year-over-year, with the annual reading at 1.58% for FY2025, 4176.0% up from the prior year.
  • EBT Margin was 19.5% for Q4 2025 at Akebia Therapeutics, down from 1.97% in the prior quarter.
  • Over five years, EBT Margin peaked at 46.31% in Q4 2021 and troughed at 159.32% in Q2 2021.
  • The 5-year median for EBT Margin is 27.14% (2023), against an average of 46.51%.
  • The largest YoY upside for EBT Margin was 30172bps in 2021 against a maximum downside of -6468bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 46.31% in 2021, then crashed by -125bps to 11.66% in 2022, then surged by 109bps to 1.09% in 2023, then crashed by -4589bps to 49.04% in 2024, then surged by 60bps to 19.5% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBT Margin are 19.5% (Q4 2025), 1.97% (Q3 2025), and 0.4% (Q2 2025).